Cyclic lipopeptides such as surfactin and polymyxin have potent mucosal adjuvant properties. Cyclic lipopeptides are tensioactive compounds, but the relationship between adjuvanticity and surface activity is unknown. Here, we show that the critical micelle concentration (cmc) of surfactant and particle size of the surfactant-protein complex are important determinants of cyclic lipopeptide adjuvanticity. We found that the diameter of cyclic lipopeptide-ovalbumin (OVA) complex particles was significantly larger than that in the solutions of OVA alone at cyclic lipopeptide concentrations above the cmc. OVA-specific antibody titres in mice immunized intranasally with OVA and a cyclic lipopeptide at concentrations above its cmc were significantly higher than those in mice immunized with OVA plus the same dose of the cyclic lipopeptide but administered with formulations in which cyclic lipopeptide concentration was below the cmc. Thus, the concentration of the cyclic lipopeptide in the formulation at immunization, but not its overall dose, was critical for its adjuvanticity. Furthermore, two types of aggregates, the cyclic lipopeptide simplex micelles and the cyclic lipopeptide-OVA complex micelles, were found in formulations with SF concentrations above its cmc.
| INTRODUCTION
An extensive vulnerable barrier of the mucosal epithelium is reinforced by numerous defence mechanisms that cooperate intimately with innate and adaptive immunity. Mucosal vaccines induce protective immune responses in the mucosal compartment along with external secretions containing specific antibodies (Abs) that act as the first line of defence at the initial invasion site. 1, 2 To induce strong immune responses to administered vaccine antigens (Ags), which would subsequently protect against mucosal infection, the addition of a mucosal adjuvant is often required. Cyclic lipopeptides represent one class of such adjuvants, 3 and many cyclic lipopeptides are produced by various bacterial genera, including Bacillus spp. Surfactin (SF), polymyxin B (PMB), colistin (CL), WH1fungin, and iturin are cyclic lipopeptides that have been isolated from Bacillus subtilis, 4 Paenibacillus polymyxa, 5 P. polymyxa tilis, 8 respectively. These polypeptide compounds have an amphiphilic structure with a hydrophilic head moiety and an alkyl chain as a hydrophobic tail moiety. 9 Amphiphilic molecules are commonly tensioactive. 10 SF was shown to have a stronger surface activity than sodium dodecyl sulfate, a synthetic surfactant. 4 The critical micelle concentration (cmc) and surface tension at the cmc (γ cmc ) of SF dissolved in deionized water are approximately 0.01 mg/ mL and 27 mN/m, respectively. 11 SF surface activity exceeds that of PMB and CL. 12 Cyclic lipopeptides described above exhibit adjuvanticity. [13] [14] [15] [16] [17] In our previous study, we compared adjuvanticity of PMB and polymyxin B nonapeptide (PMBN). PMBN has no surface activity as a consequence of terminal amino acyl group removal. 18 The adjuvanticity of PMBN was significantly lower than that of PMB. 14 This observation suggested that the potent adjuvanticity of PMB might result from its surface activity. However, it has not yet been conclusively demonstrated whether adjuvanticity is related to surface activity. Generally, surfactants lower surface tension at the airliquid interface. At low surfactant concentrations, surfactant molecules accumulate on the solution surface. When more surfactant is added, the surface tension of the solution starts to rapidly decrease because more and more surfactant molecules are present on the surface. When the concentration of the surfactant reaches cmc, the addition of the surfactant molecules leads to the formation of micelles. Each surfactant can be characterized by its cmc. 19, 20 Moreover, surfactants form aggregates with polyelectrolytes, such as proteins. 21 Surfactant-protein complex formation results from electrostatic bonding and is further stabilized by hydrophobic interactions with surfactant tails. 22 Therefore, the behaviour of surfactant in the surfactant-protein-water system is different from that in the surfactant-water system. 23 In this study, we analysed the relationship between adjuvanticity and surface activity using different tensioactive cyclic lipopeptides-SF, PMB and CL-focusing on cmcs and surfactant-protein complex properties in the surfactant-protein system.
| MATERIALS AND METHODS

| Ethics statement
All animal protocols adhered to the recommendations of the Guidelines for Proper Conduct of Animal Experiments established by the Science Council of Japan and were approved by the Committee on the Ethics of Animal Experiments (CEAE) at the Iwate Medical University. All animal experiments were performed in accordance with the guidelines set by Iwate Medical University CEAE (permit number 24-016).
| Ag and adjuvant
Ovalbumin (OVA; purity ≥98%, grade VI; Sigma-Aldrich, St. Louis, MO, USA), β-casein from bovine milk (CAS; purity ≥98%; BioUltra; Sigma-Aldrich) and bovine serum albumin (BSA; purity ≥98%, heat-shock fractions; SigmaAldrich) were employed as model antigenic proteins. SF sodium salt, PMB sulfate and CL sulfate (Wako Chemical Industries, Ltd., Osaka, Japan) were used as adjuvants. Endotoxin levels in the adjuvants were monitored by a Chromogenic Limulus Amebocyte Lysate Endotoxin Assay Kit (GenScript, Piscataway, NJ, USA), and we confirmed that endotoxin content of each adjuvant was less than 0.1 endotoxin units (EU)/mg.
| Immunization of mice
Five-week-old C57BL/6N female mice were purchased from CLEA Japan, Inc. (Tokyo, Japan). The mice were acclimated to the experimental animal facility for more than 1 week before being used in the experiments. They were housed in the facility under pathogen-free conditions. For the preparation of immunization solutions, each adjuvant and protein Ag were dissolved in normal saline (<0.25 EU/mL; Otsuka Pharmaceutical Factory, Inc., Tokushima, Japan). Mice were lightly anesthetized with ketamine before immunization with 5 μL aliquots (2.5 μL/ nostril) of normal saline containing 100 μg of OVA CAS, or BSA, and various amounts of SF, PMB or CL, while care was taken to avoid curarization. 24 Furthermore, we used three distinct immunization regimens ( Figure 3A ). All mice were immunized three times at weekly intervals, so the schedule was largely similar to that used in previous studies.
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| Assessments of Ag-specific humoral immune responses
Mucosal secretions (faecal extracts, nasal washes and saliva) and blood samples were collected as described previously [29] [30] [31] and stored at −80°C until use. Titres of OVA-, CAS-or BSA-specific Abs in mucosal secretions and plasma were determined using endpoint enzyme-linked immunosorbent assays (ELISAs). 27, 32, 33 The endpoint titres reflected the greatest dilutions that displayed an optical density of ≥0.1 OD 450 units above that of the negative controls at 450 nm (OD 450 ).
| Measurements of surface tension, pH and particle size
Sample solutions were prepared in normal saline by dissolving several dosages of adjuvant (SF, PMB or CL) and protein (OVA, CAS or BSA) and were kept at 20°C in an e-cooling bucket (Taitec Co., Saitama, Japan) for >30 minutes. Surface tension values were measured by capillary activity using a Dyne Gauge surface tension meter (Surfgauge, Chiba, Japan). The cmc of each formulation was deduced experimentally from a graph of the logarithm of the concentration of the surface-active agent plotted as a function of the interfacial tension. The concentration corresponding to the intersection of the tangents drawn through the regions of the two linear segments represented the cmc. 34 The pH values of the solutions were measured using a compact pH meter (Horiba Ltd., Kyoto, Japan). The particle diameters were analysed by dynamic light scattering by a Zetasizer nano-ZS instrument (Malvern Instruments Ltd., Worcestershire, UK) operated at a scattering angle of 173°a nd the thermostated sample chamber set to 20°C, according to the manufacturer's instructions.
| β-Hexosaminidase assay
MC/9 cells, a murine mast cell clone derived from mouse fetal liver (American Type Culture Collection, Manassas, VA, USA, catalogue number: CRL-8306), 35 were employed for the β-hexosaminidase assay. Culture conditions and methods of the β-hexosaminidase assay were described in detail previously.
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| Statistical analysis
The titres of Ag-specific Abs are expressed as the median with interquartile range. 37 Comparison of the titres of Ag- we assessed surface tension values and particle sizes in cyclic lipopeptide-protein systems. Plotting surface tension values vs the concentration of the SF-OVA-saline system showed a sharp decrease in surface tension up to the cmc, beyond which it stabilized. The cmc of the SF-OVA-saline system was determined to be 0.328 mg/mL (γ cmc = 28.2 mN/m) ( Figure 1A ). Likewise, lower surface tension values were observed in the PMB-OVA-saline and CL-OVA-saline systems. The cmcs of PMB and CL were determined to be 26.6 mg/mL (γ cmc = 39.5 mN/m) and 22.3 mg/mL (γ cmc = 39.8 mN/m), respectively ( Figure 1A) . Next, we measured diameters of the particles in the solutions of cyclic lipopeptides at concentrations above their cmcs. The mean dominant particle diameters in solutions comprising 100 mg/mL SF plus 20 mg/mL OVA, 100 mg/mL SF, and 20 mg/mL OVA were 195.1, 7.3 and 25.9 nm, respectively. The dominant sizes of particles in the solutions containing both cyclic lipopeptide and OVA were significantly larger than those in the solutions of cyclic lipopeptides or OVA alone ( Figure 1B ). These data suggested that cyclic lipopeptides formed aggregates with OVA.
| Humoral immune responses and surface activity parameters
Based on cmc values determined in cyclic lipopeptide-OVA systems, mice were intranasally immunized using the following regimens: OVA without cyclic lipopeptide (group N), OVA with cyclic lipopeptide at a concentration below its cmc (group B) and OVA with cyclic lipopeptide at a concentration above its cmc (group A). Finally, in group H (used only in experiments with SF), mice were immunized with OVA plus SF at a high dose of 500 μg/ mouse, which was the dose used for group A mice in experiments for PMB and CL ( Figure 2 ). At 1 week after the last immunization, the levels of OVA-specific IgA Abs in the nasal washes and IgG Abs in the plasma of mice were determined by endpoint ELISAs. All cyclic lipopeptides tested (SF, PMB, and CL) significantly enhanced OVA-specific Ab titres in both nasal washes and plasma samples of group A as compared to those in group N animals. The titres of OVA-specific Abs in the nasal washes and plasma samples of group H mice were also significantly higher than those of group N mice. However, there were no significant differences between the titres in mucosal and systemic compartments between group N and group B animals ( Figure 2 ). These findings suggested that cyclic lipopeptides exhibit maximal adjuvanticity if they are used at concentrations above their cmc. In general, the strength of the immune response is potentiated by the adjuvant in a dose-dependent manner. 38 Therefore, we assessed how the efficacy of a cyclic lipopeptide as an adjuvant is determined by dosing YOSHINO ET AL.
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frequency and concentration of the adjuvant. Three groups of mice received identical amounts of SF (5 μg/mouse) and OVA (100 μg/mouse), but the pattern of dosing varied ( Figure 3A ): group 1 mice received SF and OVA in 10 administrations of 0.2 mg/mL SF (below the cmc) and 4 mg/mL OVA in the left and right nostrils; group 2 mice received SF and OVA in two administrations of 1 mg/mL SF (above the cmc) and 20 mg/mL OVA; and group 3 mice were immunized once with 1 mg/mL SF (above the cmc) and 20 mg/mL OVA into the left nostril, subsequently inoculated alternatively with normal saline eight times in the right and left nostrils and finally immunized again with 1 mg/mL SF and 20 mg/mL OVA into the right nostril ( Figure 3A) .
The titres of OVA-specific IgA Ab in the nasal washes and IgG Ab in the plasma of group 1 mice were significantly lower than those of group 2 animals. The volumes of immunization solutions were different between group 1 and group 2 mice, whereas in group 3 mice, the volume used for immunization was equal to that in group 1 animals, but the concentrations of OVA and SF were different from those of group 1 animals. OVA-specific Ab titres in the nasal washes and plasma of group 1 mice were also significantly lower than those of group 3. Moreover, the titres of IgA Abs in faecal extracts and saliva of group 3 mice tended to be higher than those in group 1, although those differences were not statistically significant. It should be noted that the levels of OVA-specific IgA Abs in the nasal washes and saliva of all mice in group 1 were below the detection limit. Furthermore, the titres of OVA-specific IgA Ab in mucosal secretions and IgG Abs in the plasma of group 2 and group 3 mice were similar, whereas the immunization volume was different ( Figure 3B ). These findings in the three groups of immunized mice indicated that SF adjuvanticity was more pronounced when it was administered at a concentration above its cmc. We therefore concluded that the adjuvanticity of cyclic lipopeptide is likely determined more by its concentration in the dosing solution, particularly by the fact whether it is higher than cmc, rather than by the number of individual doses. and 20 mg/mL, respectively. Each dot represents an individual measurement. Horizontal and vertical bars indicate the mean ± SD of three independent experiments. Significant differences between particle diameters in formulations containing cyclic lipopeptide alone (−) and cyclic lipopeptide plus OVA (+) are indicated with asterisks as follows: **P < 0.005. Significant differences between particle diameters in formulations containing OVA alone and OVA plus cyclic lipopeptide are indicated with hash signs as follows: ## P < 0.005
| Size of SF-OVA-saline system particles
We measured the size of particles in the immunization solution and found that the mean particle diameter in the SF-saline system was 7.3 nm (Table 1; Figure 4) . Particles of the same size were observed in the SF-OVA-saline systems with both 1 mg/mL SF and 100 mg/mL SF. At concentrations of SF above its cmc (>0.328 mg/mL SF), two different particle sizes were observed in the SF-OVA-saline system, with the larger particles being predominant ( Table 1 ). The mean dominant particle size in 20 mg/mL OVA and 1 mg/mL SF solutions (groups 2 and 3 in Figure 3) was significantly larger than that in 4 mg/mL OVA and 0.2 mg/mL SF solution (group 1 in Figure 3) . Moreover, the particle sizes in the solution used to immunize group 1 animals in Figure 3 were not significantly different from those of OVA alone (Figure 4) . The pH values of all solutions were between 6.6 and 7.0 (Table 1) . It was presumed that the particle size of SF-OVA complexes in preparations containing SF at concentrations above its cmc was related to enhanced humoral immune responses.
| Adjuvanticity for other proteins
CAS and BSA were also employed to assess SF adjuvanticity. First, we measured surface tension values in the SF-CAS-saline and SF-BSA-saline systems. cmc values of the SF-CAS-saline and SF-BSA-saline systems were 1.96 mg/ mL (γ cmc = 27.0 mN/m) and 1.85 mg/mL (γ cmc = 28.0 mN/m), respectively ( Figure 5A ). As shown in Figure 1A , the cmc of the SF-OVA-saline system was 0.328 mg/mL (γ cmc = 28.2 mN/m). Although the values of γ cmc were roughly equivalent in these systems, the cmcs varied depending on the protein used. Next, we measured particle sizes in the SF-CAS-saline or SF-BSA-saline systems, in which SF concentration was above its cmc. The mean particle diameters in 100 mg/mL SF plus 20 mg/mL CAS and 20 mg/mL CAS were 77.6 and 42.3 nm, respectively. The mean particle sizes in the SF-CAS-saline system were significantly larger than those in the CAS-saline system. A significant increase in the particle diameter due to the presence of SF was also observed in the BSA system ( Figure 5B ). The mean particle diameter in the SF-OVA-saline system was 195.1 nm ( Figure 1B) .
F I G U R E 2 Relationship Between the Critical Micelle
Concentration and Ovalbumin-specific Antibody Titre. Mice were intranasally immunized three times at weekly intervals as follows: (a) ovalbumin (OVA) without cyclic lipopeptide (group N), (b) OVA with cyclic lipopeptide at a concentration below its cmc (group B) and (c) OVA with cyclic lipopeptide at a concentration above its cmc (groups A and H). In the experiments with SF-containing formulations, the concentrations of SF in the immunization solutions of group B (0.5 μg SF/mouse), group A (5 μg SF/mouse) and group H (500 μg SF/mouse) mice were 0.1 mg/mL (below the cmc), 1 mg/ mL (above the cmc) and 100 mg/mL (above the cmc), respectively. In the experiments with PMB-or CL-containing formulations, their concentrations in the immunization solutions of group B (50 μg PMB or CL/mouse) and group A (500 μg PMB or CL/mouse) mice were 10 mg/mL (below the cmc) and 100 mg/mL (above the cmc), respectively. The nasal washes and plasma samples were collected at 1 week after the last immunization, and the OVA-specific IgA and IgG antibody levels were determined by endpoint enzyme-linked immunosorbent assay. Data are presented as the median with interquartile range of two independent experiments (with eight mice in each experimental group). Horizontal lines indicate the measurement limit. Significant differences are indicated with asterisks as follows: *P < 0.05, **P < 0.005
The sizes of both SF-CAS and SF-BSA aggregates were smaller than those of SF-OVA particles.
Then, we assessed humoral immune response to establish the level of SF adjuvanticity for CAS and BSA. Mice were intranasally immunized with CAS or BSA plus SF using the same methods and schedules as those used with OVA. The titres of CAS-or BSA-specific IgA Abs in mucosal secretions of mice immunized with or without SF Scheme of immunization. Group 1: Mice were immunized 10 times alternatively with 0.2 mg/mL SF (below the critical micelle concentration, (cmc)) and 4 mg/mL ovalbumin (OVA) into the left and right nostrils (total 5 μg surfactin (SF)/mouse and 100 μg OVA/mouse in at least a 25 μL volume). Group 2: Mice were immunized with 1 mg/mL SF (above the cmc) and 20 mg/mL OVA into each nostril (total 5 μg SF/mouse and 100 μg OVA/mouse in at least a 5 μL volume). Group 3: Mice were immunized with 1 mg/mL SF (above the cmc) and 20 mg/mL OVA in the left nostril, subsequently inoculated alternatively with normal saline eight times into the right and left nostrils and finally immunized with 1 mg/mL SF and OVA into the right nostril (total 5 μg SF/mouse and 100 μg OVA/mouse in at least a 25 μL volume). All groups of mice were immunized with each regimen three times at weekly intervals. L, immunization into the left nostril; R, immunization into the right nostril. B, Mucosal secretions and plasma were collected 1 week after the last immunization, and OVA-specific IgA and IgG antibody levels were determined by endpoint enzyme-linked immunosorbent assay. Each dot represents a measurement from an individual mouse. Data are expressed as the median with interquartile range of two independent experiments (with eight mice in each experimental group). Horizontal lines indicate the measurement limit. Significant differences are indicated with asterisks as follows: **P < 0.005 The ranges are shown as the minimum and maximum diameters of all experiments in each concentration.
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6 of 12 | were mostly below the detection limit of ELISAs. Meanwhile, the titres of CAS-or BSA-specific IgG Abs in the plasma of mice immunized with CAS or BSA plus SF were significantly higher than those in mice immunized with CAS or BSA alone ( Figure 5C ). SF adjuvanticity properties in the case of CAS and BSA were weaker than in the case of OVA. These findings suggest that the larger particle diameter conferred by SF presence could be a critical factor of SF adjuvanticity.
| Mast cell activation in the SF-OVA system
The above results demonstrated that the cmc was an important parameter that likely determined the adjuvanticity of cyclic lipopeptides. Our previous study showed that SF directly activated mast cells. 17 We therefore used the β-hexosaminidase assay to clarify whether cmc value affected mast cell activation. It has been shown previously that mast cell activation is induced by concentrations of SF ≥10 μg/ mL. First, we measured surface tension values of solutions containing 10 μg/mL SF with or without various concentrations of OVA. The surface tension of the SF-saline system was 29.1 mN/m. At OVA concentrations up to 100 μg/mL, there were no differences in surface tension values between the SF-OVA-saline and SF-saline systems. At OVA concentrations ≥200 μg/mL, surface tension values significantly increased in a dose-dependent fashion ( Figure 6A ). Next, we assessed β-hexosaminidase release in solutions containing 10 μg/mL SF and 0, 10, 100 or 1000 μg/mL OVA. The amount of β-hexosaminidase released in the solution containing 1000 μg/mL OVA and 10 μg/mL SF was significantly lower than that in SF solution without OVA. In contrast, the amounts of β-hexosaminidase released in solutions containing 10 or 100 μg/mL OVA were not significantly different from those in SF solution without OVA ( Figure 6B ). These results suggested that SF itself, but not the SF-OVA complex, activated mast cell degranulation.
| DISCUSSION
In this study, we focused on the surface activity of cyclic lipopeptides and its relation to their adjuvanticity. First, we determined surface-active properties and cmc of cyclic lipopeptides and their interactions with proteins in cyclic lipopeptide-protein systems. The spherical micelles of SF were 5-9 nm in diameter at pH 7 according to electron cryomicroscopy observations. In contrast, at pH 9.5, the cylindrical SF micelles had been observed previously that were 40-160 nm in length and 10-14 nm in width. 39 The diameter of colistin micelles has been reported to be 2.07 ± 0.30 nm. 12 As shown in Figure 1B , particle diameters in SF-, PMB-and CL-saline systems at above their cmcs were 7.28 ± 0.69, 2.54 ± 0.42 and 2.07 ± 0.03 nm, respectively. Our results broadly corresponded to the values from previous reports. Hence, in our study, we reconfirmed the self-assembly of cyclic lipopeptides in the systems where their concentrations were above the respective cmc values. Meanwhile, significantly larger particles were detected in the cyclic lipopeptide-OVA-saline systems. Binding of ionic surfactants to proteins proceeds via sequential steps. 22, 40, 41 The first binding steps involve individual monomers binding via electrostatic and hydrophobic interactions. The alkyl chains associate with the nearby hydrophobic moieties of the proteins. At higher concentrations, when the initial binding sites are saturated, binding of additional surfactants can lead to cluster formation and self-assembly. Although a single particle size was predominantly observed at concentrations of surfactants below the cmc in our study, particles of two different sizes existed in the SF-OVA systems in which SF concentration was above the cmc. As shown in Table 1 , the smaller particle sizes in OVA solutions containing 100 mg/mL or 1 mg/mL SF were roughly equivalent to the size of particles seen in the SF-saline system. It can be concluded that these smaller particles were SF simplex micelles, whereas the larger particles in the solutions of OVA and 1 mg/mL or 100 mg/ mL SF were SF-OVA complexes. To investigate the relationship between the cmc and adjuvanticity, we compared immune responses in mice intranasally immunized with OVA and one of the three tested cyclic lipopeptides. After immunizations with OVA plus a cyclic lipopeptide at a dose of 500 μg/mouse (concentration in the immunization solution: 100 mg/mL), no significant difference was observed in the titres of OVA-specific IgA and IgG Ab between the groups of mice exposed to different surfactants. In contrast, whereas OVAspecific immune responses were potently enhanced by SF Horizontal and vertical bars indicate the mean ± SD of three independent experiments. Significant differences between particle diameters in formulations containing CAS or BSA alone (−) and CAS or BSA plus SF (+) are indicated with asterisks as follows: *P < 0.05. C, Mice were intranasally immunized three times with CAS or BSA with or without 500 μg of SF, at weekly intervals. Mucosal secretions and plasma were collected at 1 week after the last immunization, and CAS-or BSA-specific IgA and IgG antibody levels were determined by endpoint enzyme-linked immunosorbent assay. Each dot represents a measurement from an individual mouse. The results are expressed as the median with interquartile range of two independent experiments (with eight mice in each experimental group). Horizontal lines indicate the measurement limit. Significant differences are indicated with asterisks as follows: **P < 0.005 at a dose of 5 μg/mouse (1 mg/mL), PMB and CL failed to produce a significant effect at a dose of 50 μg/mouse (10 mg/mL). It was likely because cyclic lipopeptide concentrations used for these doses (1 mg/mL SF, 10 mg/mL PMB and 10 mg/mL CL) were higher than the cmc for SF, but lower than the respective cmcs for PMB and CL.
This comparison also suggested that cmc values of cyclic lipopeptides are inversely proportional to their adjuvanticity. The primary difference between the structures of SF and PMB is the length of their alkyl chains: the number of carbon atoms in the alkyl chains of SF and PMB is 11 and 6-7, respectively. [42] [43] [44] Micelle sizes and shapes depend on the alkyl chain length and hydrophilic groups. 45 To enhance immunity, it may be beneficial to adjust the number of carbon atoms in the alkyl chain of the hydrophobic group of cyclic lipopeptides. Herein, we demonstrated that immunization preparations in which SF concentration was higher than the cmc had higher adjuvanticity and were associated with larger SF-OVA complex particles. Because particle size influences the competence of immune responses induced by vaccination, 46 it must be considered when vaccine formulations are intended for intranasal immunization. 47, 48 It has been frequently reported that particle size influences immune responses. [48] [49] [50] [51] [52] [53] [54] [55] [56] With regard to vaccine Ags, it has been noted that only particles in the nanometre range, that is of the size of viruses, can reach lymph nodes and directly interact with B cells, inducing potent immune responses. 48, 50 Comparisons of silica nanoparticle vaccines that contained particles of different diameters demonstrated that particles of the most effective formulations were 30-50 nm in diameter. 49, 54, 55 Synthetic haemozoin preparations that comprised 50-200-nm particles exhibited a stronger adjuvant effect compared with preparations with larger (2-20 μm) or smaller (<50 nm) particles. 51 As was noted in studies of poly(lactic-co-glycolic acid) (PLGA) particle vaccine, a decrease in the diameter of PLGA particles with co-encapsulated CpG and OVA from 7 μm to 300 nm led to an increase in the titres of OVA-specific IgG Ab. 52 In addition, 357-nm PLGA particles with coencapsulated poly(I:C) and OVA induced a stronger OVAspecific IgG response than did 17-μm particles with the same composition. 53 Furthermore, the frequency of murine cytomegalovirus-specific cytotoxic T lymphocytes was significantly higher in both mucosal and systemic tissues of mice immunized intratracheally with 350-nm PLGA nanoparticles with encapsulated peptide vaccine than after the immunization with 5.4-μm PLGA microparticles. 56 Although the optimal size of silica nanoparticles for the induction of immune response was smaller than that used in other vaccines, these previous reports suggested that 100-500-nm particles can be adapted for vaccine preparations. In the current study, the particle diameter of the SF-OVA complex in the SF-OVAsaline system with 100 mg/mL SF was 122-255 nm, whereas the diameter of particles in the OVA-saline system was only 24-48 nm. We hypothesize that mucosal adjuvanticity of SF was due to the formation of SF-OVA complexes of appropriate size when SF concentration was above the cmc. To elucidate whether there was a direct relationship between particle size and immune responses, we assessed the titres of OVA-specific Ab following three distinct immunization regimens described in Figure 3A . Those experiments clearly demonstrated that even when total dosages of SF and OVA were sufficiently high to enhance immune responses, immunization with preparations of suboptimal SF-OVA complex particle size did not increase SF adjuvanticity. For F I G U R E 6 Surface Tension and Mast Cell Activation in the Surfactin-Ovalbumin System. A, Surface tension values were measured in the solutions containing 10-500 μg/mL ovalbumin (OVA) and 10 μg/mL SF at 20°C. The horizontal line indicates the surface tension value of a 10 μg/mL surfactin (SF) solution (29.1 ± 1.0 mN/m). Data are presented as the mean ± SD from three independent experiments. Significant differences between surface tension values in solutions containing SF alone and SF plus OVA are indicated with asterisks (*P < 0.05, **P < 0.005). B, Degranulation of MC/9 cells was assessed by the β-hexosaminidase release assay. MC/9 cells were cultured with 10 μg/mL SF plus 0, 10, 100 or 1000 μg/mL OVA. Data are presented as the mean ± SD of five independent experiments. Significant differences are indicated by asterisks as follows: **P < 0.005 maximal adjuvanticity, SF concentration apparently had to be above the cmc, which caused the formation of larger SF-OVA complex particles. In contrast, the dosage administered was not the determining factor for adjuvanticity.
By utilizing other Ags, we confirmed the adjuvanticity of cyclic lipopeptides tested. It has been reported that CAS and BSA formed protein-anionic surfactant complexes at concentrations above the cmc of the surfactant.
57,58 Accordingly, we employed CAS and BSA as model Ags. SF enhanced the titre of CAS-and BSA-specific IgG Abs in the plasma. However, Ab titres in mucosal secretions of mice immunized with SF and CAS or BSA were mostly below the detection limit. The immunogenicity of CAS and BSA differed from that of OVA, as was observed by measuring the plasma titres of specific IgG Abs of mice immunized with each Ag alone. However, we considered that this finding might have resulted from the fact that the SF-CAS-saline and SF-BSAsaline systems have smaller particles than agglomerates of the SF-OVA-saline system. Mean particle diameters in the SF-CAS-saline and SF-BSA-saline systems were less than 100 nm. Although the biodistribution of proteins immunized intranasally with or without cyclic lipopeptides was not examined in this study, it has been shown that the transport of nanoparticles from the nasal cavity to the bloodstream after nasal application was highly dependent on the particle size, and those were smaller (20-nm) particles that predominantly reached the bloodstream. 59 Therefore, we supposed that CAS-and BSA-specific mucosal immune responses were weakly induced because the respective adjuvant-protein complexes had a small particle size. As a supplement, we assessed the adjuvanticity of cyclic lipopeptide by utilizing mouse-adapted whole inactivated influenza A virus (WIIV). Immunization solutions were dispensed by 10 μg/mL of WIIV with or without 50 mg/mL of PMB (above its cmc) in saline. Mean particle diameters in WIIV-saline and PMB-WIIV-saline systems were 156.5 and 193.6 nm, respectively. The mean particle diameter in PMB-WIIV-saline system was significantly larger than that of WIIV-saline system (Student's t test; P < 0.05). Mice were intranasally immunized with 10 μL aliquots of each immunization solution described above on days 0 and 28. Two weeks after the last immunization, nasal washes and blood were collected. The median reciprocal log 2 titres of WIIVspecific IgA Ab in nasal washes of mice immunized with WIIV alone or WIIV plus PMB were 3.0 (range; 1-5) or 5.0 (range; 3-7), respectively. The titres of WIIV-specific IgA Abs in the nasal wash samples of mice immunized WIIV plus PMB were significantly higher than those of mice immunized with WIIV alone (Mann-Whitney U test; P < 0.05), although there were no significant differences of WIIV-specific IgG Abs in plasma between both groups. After challenge of lethal dose of homologous mouse-adapted influenza viruses, all non-immunized mice gradually lost weight and died. In contrast, no mortality was observed in both immunized groups. However, body weight of mice immunized with WIIV alone was significantly lower than that of mice immunized with WIIVs plus PMB after challenge (two-way ANOVA; P < 0.005). Conversely, there were no significant differences in weight loss between mice immunized with WIIVs plus PMB and naïve non-challenged mice. Accordingly, no morbidity and mortality were observed in mice intranasally immunized with WIIVs plus PMB after lethal doses of mouse-adapted influenza A virus challenge (Y. Sasaki, personal communications). We concluded that increase in the diameter of such particles amply afforded by cyclic lipopeptide was the basis of cyclic lipopeptide adjuvanticity.
In a previous study, using mast cell-deficient mice, we demonstrated that mast cells participated in the manifestation of SF adjuvanticity. 17 PMB and CL also were shown to induce mast cell degranulation and histamine release.
14 However, the relationship between surfactant cmc and mast cell activation has not been examined. At concentrations of SF above its cmc in the SF-OVA-saline system, both SF simplex and SF-OVA complex micelles were found ( Table 1) . As shown in Figure 6A , SF molecules were present on the air-water interface, forming a layer, and in the solution, forming SF micelles in the SF-saline system. Some SF molecules bonded to OVA if OVA concentration was below 100 μg/mL, whereas the rest of the SF molecules were saturated on the air-water interface. We believe that the three states of SF (SF monomer, SF micelle and SF-OVA complex) might have counterpoised each other. In contrast, at OVA concentrations above 200 μg/mL, the levels of SF monomers and SF micelles in the aqueous phase were reduced by the forming SF-OVA complex. This meant that the SF-OVA complex principally existed in the solutions with OVA concentrations above 200 μg/mL. Therefore, the SF-OVA complex could not induce mast cell degranulation. Taken together, cyclic lipopeptides such as SF apparently upregulate antigen-induced immune response by two ways: by expanding the size of the formed surfactant-antigen complex particles and by activating mast cells with surfactant simplex micelles. The results of this study suggested that the cmc and surfactant-antigen particle size are the key parameters of the adjuvanticity of cyclic lipopeptides. Furthermore, this study may have important repercussions for animal welfare. Usually, candidate adjuvants are tested in several experimental groups at different doses during preliminary examinations to determine the optimal adjuvant dosages in vivo. Our findings suggest that optimal immunization regimen and, in particular, the concentration and dosage of the immunization solution should take into account the cmc of the surfactant and the particle size of cyclic lipopeptide-protein systems in vitro. The use of this information will help to design adequate experimental protocols and reduce the number of animals. Whereas future studies will need to assess the uptake of cyclic lipopeptide-protein complexes at the nasal cavity and examine biokinetics of proteins, our data advance a novel concept that the absolute dosage of cyclic lipopeptide is less important than its concentration in individual vaccine solutions used for the induction of specific immune responses. We anticipate that our study will initiate further investigations of this topic, which is on the boundary between immunology and physical chemistry.
